Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM2 | P31350 | 5/20 | 0.61 |
| ▸ | RRM1 | P23921 | 1/20 | 0.61 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.61 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CTH | P32929 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882894 | 1.00 | RRM2 (0.61) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL29569419 | 1.00 | RRM2 (0.61) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL8684404 | 0.85 | RRM2 (0.57) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL8683080 | 0.79 | RRM2 (0.50) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL29370 | 0.76 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL29365763 | 0.76 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL29362841 | 0.76 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL29371 | 0.76 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL31238438 | 0.76 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL29773649 | 0.73 | NCOA3 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344618-B2 | HIV envelope glycoprotein immunogens | ACADEMISCH MEDISCH CENTRUM (NL) | 2022-05-31 | — | — | US | disclosed |
| US-20200353069-A1 | IMPROVED HIV ENVELOPE GLYCOPROTEIN IMMUNOGENS | Stichting Amsterdam UMC (NL) | 2020-11-12 | — | — | US | disclosed |
| EP-3672983-A1 | IMPROVED HIV ENVELOPE GLYCOPROTEIN IMMUNOGENS | Academisch Medisch Centrum (NL) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019042950-A1 | IMPROVED HIV ENVELOPE GLYCOPROTEIN IMMUNOGENS | ACADEMISCH MEDISCH CENTRUM (NL) | 2019-03-07 | — | — | WO | disclosed |
| CN-101302192-B | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC | 2014-01-22 | — | — | CN | disclosed |
| US-20110250220-A1 | MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF | PROGENICS PHARMACEUTICAL: INC.: and CORNELL RESEARCH FOUNDATION INC. | 2011-10-13 | — | — | US | disclosed |
| US-7939083-B2 | Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain | PROGENICS PHARMACEUTICALS INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100041875-A1 | MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COPLEXES, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| EP-2073840-A2 | MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| CN-101302192-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | CN | disclosed |
| EP-0984932-A1 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | Vion Pharmaceuticals, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0984932-A1 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | Vion Pharmaceuticals, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5869676-A | Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5869676-A | Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998051670-A1 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998051670-A1 | PROCESS FOR THE SYNTHESIS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998051669-A1 | PRODRUG FORMS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998051669-A1 | PRODRUG FORMS OF RIBONUCLEOTIDE REDUCTASE INHIBITORS 3-AP AND 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| US-5767134-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5767134-A | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP | VION PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |